Wockhardt announced that it has been awarded a six-month extension of its agreement with the UK Government to fill-finish
COVID-19 vaccines. This expands the original agreement from 18 to 24 months i.e., until
August 2022 and the manufacturing will continue to be undertaken at CP Pharmaceuticals, a
subsidiary of Wockhardt based in Wrexham, North Wales.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
